Abstract
A disintegrin and metalloproteinase 17 (ADAM17) regulates key cellular processes including proliferation and migration through the shedding of a diverse array of substrates such as epidermal growth factor receptor (EGFR) ligands. ADAM17 is implicated in the pathogenesis of many diseases including rheumatoid arthritis and cancers such as head and neck squamous cell carcinoma (HNSCC). As a central mediator of cellular events, overexpressed EGFR is a validated molecular target in HNSCC. However, EGFR inhibition constantly leads to tumour resistance. One possible mechanism of resistance is the activation of alternative EGFR family receptors and downstream pathways via the release of their ligands. Here, we report that treating human HNSCC cells in vitro with a human anti-ADAM17 inhibitory antibody, D1(A12), suppresses proliferation and motility in the absence or presence of the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Treatment with D1(A12) decreases both the endogenous and the bradykinin (BK)-stimulated shedding of HER ligands, accompanied by a reduction in the phosphorylation of HER receptors and downstream signalling pathways including STAT3, AKT and ERK. Knockdown of ADAM17, but not ADAM10, also suppresses HNSCC cell proliferation and migration. Furthermore, we show that heregulin (HRG) and heparin-binding epidermal growth factor like growth factor (HB-EGF) predominantly participate in proliferation and migration, respectively. Taken together, these results demonstrate that D1(A12)-mediated inhibition of cell proliferation, motility, phosphorylation of HER receptors and downstream signalling is achieved via reduced shedding of ADAM17 ligands. These findings underscore the importance of ADAM17 and suggest that D1(A12) might be an effective targeted agent for treating EGFR TKI-resistant HNSCC.
Introduction
Head and Neck Squamous Cell Carcinoma (HNSCC) remains a significant clinical challenge, with a 5-year survival rate stagnating at approximately 50%. While the Epidermal Growth Factor Receptor (EGFR) is a primary therapeutic target, clinical outcomes are often limited by the development of resistance to inhibitors like gefitinib. A major driver of this resistance is "bypass signaling," where cancer cells activate alternative members of the HER receptor family (HER2, HER3, and HER4) to sustain growth.
These receptors are activated by ligands that must be proteolytically "shed" from the cell membrane to become active. The enzyme ADAM17 (also known as TACE) serves as the primary "molecular scissors" for these ligands. This study investigates whether blocking ADAM17 with a specific inhibitory antibody, D1(A12), can effectively shut down this network of growth signals and overcome resistance.
Methods and Model Validation
The researchers utilized a panel of HNSCC cell lines, including SCC9, SCC12, SCC13, SCC25, and the patient-derived line SJG15, comparing them against normal human keratinocytes (KN). To validate the therapeutic target, the expression levels of ADAM17, HER family receptors, and downstream signaling molecules were assessed via Western blotting.
The study employed ELISA assays to measure ligand shedding, IncuCyte live-cell imaging for proliferation, and wound-closure assays for motility. Specificity was confirmed using siRNA-mediated knockdown of ADAM17 and the related enzyme ADAM10.
Key Insights: ADAM17 as a Master Regulator
The study identifies ADAM17 as the "major sheddase" for critical ligands such as Amphiregulin (AREG) and Heregulin (HRG) in HNSCC. By inhibiting ADAM17, the D1(A12) antibody simultaneously impacts multiple HER receptors, offering a more comprehensive blockade than targeting EGFR alone.
A significant finding was the ability of D1(A12) to break the "transactivation" loop triggered by the inflammatory peptide Bradykinin (BK). Normally, BK utilizes ADAM17 to release EGFR ligands; D1(A12) successfully prevented this inflammation-driven progression. Furthermore, the researchers discovered functional specialization among ligands: Heregulin (HRG) primarily drives cell proliferation, while Heparin-binding EGF-like growth factor (HB-EGF) is the main driver of cell migration.
Results: Efficacy of D1(A12) Inhibition
Treatment with the D1(A12) antibody demonstrated robust anti-tumor activity across multiple assays:
- Growth Inhibition: D1(A12) at 0.5 µM significantly inhibited cell proliferation compared to control human IgG (hIgG).
- Reduced Motility and Invasion: In SCC13 cells, D1(A12) reduced migration by 44% and invasive behavior by 84%.
- Biochemical Blockade: The antibody significantly decreased the shedding of AREG and HRG, leading to a marked reduction in the phosphorylation of all four HER receptors and downstream mediators like STAT3, AKT, and ERK.
Crucially, D1(A12) was found to sensitize HNSCC cells to the EGFR inhibitor gefitinib, suggesting its potential as a combination therapy to overcome drug resistance.
Conclusion and Future Directions
This research underscores the pivotal role of ADAM17 in HNSCC progression and resistance. By inhibiting the sheddase activity of ADAM17, the D1(A12) antibody provides a multi-pronged attack on HER-family signaling. While these in vitro results are promising, future work must focus on in vivo validation in HNSCC models and addressing the potential side effects of systemic ADAM17 inhibition, given its role in normal physiological processes like immune response and tissue homeostasis.
Summary updated